Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On April 29, 2025, WeightWatchers announced a pharmacy integration with Eli Lilly and Companys LillyDirect pharmacy provider, Gifthealth
Tirzepatide deep-dive Tirzepatide is made by Eli Lilly under two brand names: Mounjaro -- weekly injection, FDA-approved for type 2 diabetes in 2022 (doses 2.5 mg through 15 mg) Zepbound -- weekly injection, FDA-approved for chronic weight management in November 2023 [4] The headline trial is SURMOUNT-1: 2,539 adults without diabetes, BMI of 30 or higher (or 27 with a weight-related condition), randomized across three tirzepatide doses (5, 10, 15 mg) versus placebo for 72 weeks
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
The larger batch sizes cut down on production expenses, resulting in cost savings for veterinary practices and their clients and inventory management efficiencies for clinics and hospitals
Managing side effects through rotation Some people tolerate one medication better than the other
